WO2023036195A1 - 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 - Google Patents
一类含有氘取代的苯并噻吩类衍生物及其制备与用途 Download PDFInfo
- Publication number
- WO2023036195A1 WO2023036195A1 PCT/CN2022/117613 CN2022117613W WO2023036195A1 WO 2023036195 A1 WO2023036195 A1 WO 2023036195A1 CN 2022117613 W CN2022117613 W CN 2022117613W WO 2023036195 A1 WO2023036195 A1 WO 2023036195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- alkyl
- hydrogen
- compound
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- HQALDKFFRYFTKP-UHFFFAOYSA-N 2-[4-[4-(2-benzyl-1-benzothiophen-3-yl)phenyl]-2-bromo-6-(3-methoxyphenyl)phenoxy]acetic acid Chemical class COC1=CC=CC(C=2C(=C(Br)C=C(C=2)C=2C=CC(=CC=2)C=2C3=CC=CC=C3SC=2CC=2C=CC=CC=2)OCC(O)=O)=C1 HQALDKFFRYFTKP-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 150000002431 hydrogen Chemical class 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 34
- 238000006467 substitution reaction Methods 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 23
- 229910052805 deuterium Inorganic materials 0.000 claims description 22
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 102000002227 Interferon Type I Human genes 0.000 claims description 5
- 108010014726 Interferon Type I Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 50
- 239000000243 solution Substances 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- -1 Isobutenyl Chemical group 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 206010003402 Arthropod sting Diseases 0.000 description 10
- 208000003014 Bites and Stings Diseases 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 229940044665 STING agonist Drugs 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
- 101150007193 IFNB1 gene Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125890 compound Ia Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 2
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 2
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 2
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 2
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125876 compound 15a Drugs 0.000 description 2
- 229940126212 compound 17a Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical class C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- DFATXMYLKPCSCX-VKHMYHEASA-N (3s)-3-methyloxolane-2,5-dione Chemical compound C[C@H]1CC(=O)OC1=O DFATXMYLKPCSCX-VKHMYHEASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HKLYDUXIXBVZOQ-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol Chemical class NCC(O)(O)O HKLYDUXIXBVZOQ-UHFFFAOYSA-N 0.000 description 1
- MLFIYYDKLNZLAO-UHFFFAOYSA-N 2-aminoethane-1,1-diol Chemical class NCC(O)O MLFIYYDKLNZLAO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-FIBGUPNXSA-N 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-(trideuteriomethyl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC([2H])([2H])[2H])=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-FIBGUPNXSA-N 0.000 description 1
- BZZKEPGENYLQSC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NN(C=N1)C)OC BZZKEPGENYLQSC-FIBGUPNXSA-N 0.000 description 1
- PEACIOGDEQRHFA-KIYKJNLWSA-N 8-[(2s)-1-[[6-(4,6-dideuterio-2-methylpyrimidin-5-yl)pyrimidin-4-yl]amino]propan-2-yl]-n-methylquinoline-4-carboxamide Chemical compound [2H]C1=NC(C)=NC([2H])=C1C1=CC(NC[C@@H](C)C=2C3=NC=CC(=C3C=CC=2)C(=O)NC)=NC=N1 PEACIOGDEQRHFA-KIYKJNLWSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229940124282 BMS-986165 Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- MKXZASYAUGDDCJ-QNNIAVNKSA-N deudextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C([2H])([2H])[2H])[C@H]2CC2=CC=C(OC([2H])([2H])[2H])C=C21 MKXZASYAUGDDCJ-QNNIAVNKSA-N 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- BYXUIKZQGOPKFR-UHFFFAOYSA-N hydron;n-propan-2-ylhydroxylamine;chloride Chemical compound Cl.CC(C)NO BYXUIKZQGOPKFR-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical class IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- PURKAOJPTOLRMP-ASMGOKTBSA-N n-[2-tert-butyl-4-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-5-hydroxyphenyl]-4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=C(O)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-ASMGOKTBSA-N 0.000 description 1
- UYIGFCLDEHLNGT-UHFFFAOYSA-N n-[tert-butyl(diphenyl)silyl]oxymethanamine Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)(ONC)C1=CC=CC=C1 UYIGFCLDEHLNGT-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the invention relates to the field of biomedicine, in particular to a class of deuterium-substituted benzothiophene derivatives and their preparation and use.
- Stimulator of interferon genes is an important signaling protein in the cGAS-STING signaling pathway of innate immunity.
- cGAS recognizes the 2', 3'-cGAMP catalyzed by endogenous or exogenous dsDNA, it can bind and activate STING, promotes the transport of STING from the endoplasmic reticulum to the Golgi apparatus, thereby recruiting and phosphorylating TBK1 to activate IRF3 or NF- ⁇ B, and then induce the secretion of type I interferon and other inflammatory factors, and finally produce the effect of inhibiting tumor growth .
- activating STING can be used as one of the strategies for anti-tumor immunotherapy.
- STING agonists At present, there are a number of STING agonists in clinical trials, but most of their structural types are cyclic dinucleoside derivatives of the endogenous ligand 2',3'-cGAMP. These compounds have large molecular weight and poor stability. , Most of them can only be administered by intratumoral injection, which greatly limits the clinical application and development of STING agonists. The development of STING agonists with good pharmacokinetic properties and good biological activity is one of the urgent tasks in this field.
- deuterium atoms In the process of drug development, the introduction of deuterium atoms usually helps to optimize the pharmacokinetic properties of drug molecules and prolong the drug action time, or can reduce the toxicity of drug molecules, enhance the biological activity of drug molecules, and increase the stability of molecules And so on.
- many domestic and foreign pharmaceutical companies such as BMS, Concert, Suzhou Zelgen, etc.
- deuterium-containing drugs such as deuterated tetrabenazine, donafenib.
- deuterated drugs are in clinical trials (such as BMS-986165, VX-984, CTP-656, AVP-786, etc.). It can be seen that deuterated drugs have extensive research value and broad application prospects.
- the object of the present invention is to provide a compound represented by formula I and its preparation method and application.
- the first aspect of the present invention provides a compound represented by formula I, or its isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof,
- X is selected from the group consisting of C(O), CF 2 ;
- Y is selected from the group consisting of OR a , NHR b , N(R b ) 2 ;
- R 1 and R 4 are independently selected from the following group: hydrogen, halogen;
- R 2 and R 3 are independently deuterium-substituted or unsubstituted C1-C4 alkyl
- R 5 and R 6 are independently selected from the following group: hydrogen, halogen, C1-C4 alkyl;
- R a is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted amino, the substitution means being substituted by 1-4 substituents selected from the group consisting of deuterium, C1-C4 Alkyl, C6-C10 aryl, C6-C10 aryl-(C1-C4 alkylene);
- R b is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, the substitution means being selected from the group 1-4 substituents: hydrogen, deuterium, halogen, C1-C4 alkyl, C6-C10 aryl;
- the additional proviso is that at least one of R 2 , R 3 , Ra, R b contains deuterium.
- X is C(O);
- Y is selected from the group consisting of OR a , NHR b , N(R b ) 2 ;
- R 1 and R 4 are independently selected from the following group: hydrogen, halogen;
- R 2 and R 3 are independently deuterium-substituted C1-C4 alkyl
- R 5 and R 6 are independently selected from the following group: hydrogen, halogen, C1-C4 alkyl;
- R a is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted amino, the substitution means being substituted by 1-4 substituents selected from the group consisting of deuterium, C1-C4 Alkyl, C6-C10 aryl, C6-C10 aryl-(C1-C4 alkylene);
- R b is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, the substitution means being selected from the group Substitution of 1-4 substituents: hydrogen, deuterium, halogen, C1-C4 alkyl, C6-C10 aryl.
- X is C(O);
- Y is selected from the group consisting of OR a , NHR b , N(R b ) 2 ;
- R 1 and R 4 are independently selected from the following group: hydrogen, halogen;
- R 2 and R 3 are independently deuterium-substituted C1-C4 alkyl
- R 5 and R 6 are independently selected from the following group: hydrogen, halogen, C1-C4 alkyl;
- R a is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted amino, the substitution means being substituted by 1-4 substituents selected from the group: C1-C4 alkyl , C6-C10 aryl, C6-C10 aryl-(C1-C4 alkylene);
- R b is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, the substitution means being selected from the group Substitution of 1-4 substituents: hydrogen, halogen, C1-C4 alkyl, C6-C10 aryl.
- X is CF 2 ;
- Y is selected from the group consisting of OR a , NHR b , N(R b ) 2 ;
- R 1 and R 4 are independently selected from the following group: hydrogen, halogen;
- R 2 and R 3 are independently deuterium-substituted C1-C4 alkyl
- R 5 and R 6 are independently selected from the following group: hydrogen, halogen, C1-C4 alkyl;
- R a is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted amino, the substitution means being substituted by 1-4 substituents selected from the group consisting of deuterium, C1-C4 Alkyl, C6-C10 aryl, C6-C10 aryl-(C1-C4 alkylene);
- R b is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, the substitution means being selected from the group Substitution of 1-4 substituents: hydrogen, deuterium, halogen, C1-C4 alkyl, C6-C10 aryl.
- X is CF 2 ;
- Y is selected from the group consisting of OR a , NHR b , N(R b ) 2 ;
- R 1 and R 4 are independently selected from the following group: hydrogen, halogen;
- R 2 and R 3 are independently deuterium-substituted C1-C4 alkyl
- R 5 and R 6 are independently selected from the following group: hydrogen, halogen, C1-C4 alkyl;
- R a is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted amino, the substitution means being substituted by 1-4 substituents selected from the group: C1-C4 alkyl , C6-C10 aryl, C6-C10 aryl-(C1-C4 alkylene);
- R b is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, the substitution means being selected from the group Substitution of 1-4 substituents: hydrogen, halogen, C1-C4 alkyl, C6-C10 aryl.
- R 1 and R 4 are independently selected from the group consisting of hydrogen and halogen.
- R 2 and R 3 are independently deuterated or fully deuterated C1-C4 alkyl groups one or more times.
- R 2 and R 3 are each independently one or more deuterated or fully deuterated groups selected from the following group: methyl, ethyl, propyl, isopropyl, butyl , tert-butyl.
- R 2 and R 3 are independently selected from the following group: perdeuteromethyl, perdeuteroethyl, perdeuteropropyl, perdeuteroisopropyl, perdeuterobutyl , All deuterated tert-butyl.
- both R 2 and R 3 are perdeuteromethyl.
- R 5 and R 6 are independently selected from the following group: hydrogen, C1-C4 alkyl.
- R a is selected from the group consisting of hydrogen, substituted or unsubstituted amino, said substitution means being substituted by 1-4 substituents selected from the group consisting of deuterium and C1-C4 alkyl.
- each occurrence of R b is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, hydroxyl, substituted or unsubstituted C1-C4 alkoxy, said Substitution refers to being substituted by 1-4 substituents selected from the group consisting of deuterium, C1-C4 alkyl, and C6-C10 aryl.
- R a is not deuterated.
- R b is not deuterated.
- the compound is selected from the following group:
- a second aspect of the present invention provides a pharmaceutical composition comprising:
- the third aspect of the present invention provides a compound described in the first aspect of the present invention, or its isomer, prodrug, solvate, hydrate or a pharmaceutically acceptable salt thereof or the second aspect of the present invention
- the use of the pharmaceutical composition is used for preparing a preparation, and the preparation is used for preventing and/or treating diseases related to type I interferon.
- the type I interferon-related diseases are selected from the group consisting of infectious diseases, cancer, and autoimmune diseases.
- the cancer is selected from the group consisting of breast cancer, ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, and gastric cancer.
- Figure 1 is the result of tumor inhibition by compound S1 of Example 3.
- halogen refers to F, Cl, Br or I.
- C1-C6 alkyl refers to a linear or branched alkyl group including 1-6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl group, tert-butyl group, neopentyl group, tertyl group, or similar groups.
- C1-C4 alkyl has a similar meaning.
- C2-C6 alkenyl refers to a straight chain or branched alkenyl group with 2-6 carbon atoms containing a double bond, including non-limiting ethenyl, propenyl, butenyl , Isobutenyl, Pentenyl and Hexenyl etc.
- C2-C6 alkynyl refers to a straight-chain or branched-chain alkynyl group with 2-6 carbon atoms containing a triple bond, including without limitation ethynyl, propynyl, butynyl, group, isobutynyl, pentynyl and hexynyl, etc.
- C3-C8 cycloalkyl refers to a cyclic alkyl group having 3-8 carbon atoms in the ring, including without limitation cyclopropyl, cyclobutyl, cyclopentyl, cyclo Hexyl, cycloheptyl, cyclooctyl, etc.
- C1-C6 alkoxy refers to a straight-chain or branched alkoxy group with 1-6 carbon atoms, including without limitation methoxy, ethoxy, propoxy, Isopropoxy and butoxy, etc. Preference is given to C1-C4 alkoxy.
- aromatic ring or “aryl” has the same meaning, preferably “C6-C10 aryl”.
- C6-C10 aryl refers to an aromatic ring group having 6-10 carbon atoms without heteroatoms in the ring, such as phenyl, naphthyl and the like.
- halo refers to substitution by halogen.
- deuterated refers to substitution by deuterium.
- substituted means that one or more hydrogen atoms on a specific group are replaced by a specific substituent.
- the specific substituents are the corresponding substituents described above, or the substituents appearing in each embodiment.
- a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituents may be the same or different at each position.
- substituents contemplated by this invention are those that are stable or chemically feasible.
- the substituents are for example (but not limited to): halogen, hydroxyl, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclic group, aryl group, heteroaryl group, C1-C8 aldehyde group, C2-C10 acyl group, C2-C10 ester group, amino group, C1-C6 alkoxy group, C1-C10 sulfonyl group, etc.
- the term 1-6 means 1, 2, 3, 4, 5 or 6. Other similar terms each independently have a similar meaning.
- amino is -NH2.
- the present invention provides the compound represented by formula I, or its isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof,
- each group is as defined above.
- the term "pharmaceutically acceptable salt” refers to a salt of a compound of the present invention with an acid or a base which is suitable for use as a medicine.
- Pharmaceutically acceptable salts include inorganic salts and organic salts.
- a preferred class of salts are the salts of the compounds of the invention with acids.
- Acids suitable for forming salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid; formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, Fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and other organic acids; Amino acids such as amino acid, phenylalanine, aspartic acid, and glutamic acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid
- salts of the compounds of the present invention with bases such as alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts (e.g. magnesium or calcium salts), ammonium salts (e.g.
- lower alkanolammonium salts and other pharmaceutically acceptable amine salts such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butyl amine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.
- methylamine salts such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butyl amine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salt
- solvate refers to a complex in which a compound of the present invention coordinates with solvent molecules to form a specific ratio.
- “Hydrate” refers to a complex formed by coordination between the compound of the present invention and water.
- the compounds of the present invention also include prodrugs of the compounds represented by formula I.
- prodrug includes itself may be biologically active or inactive, when administered in an appropriate manner, it undergoes metabolism or chemical reactions in the human body to convert into a class of compounds of formula I, or formula I A salt or solution of a compound.
- the prodrugs include (but are not limited to) carboxylates, carbonates, phosphates, nitrates, sulfates, sulfone esters, sulfoxide esters, amino compounds, carbamates, azo compounds of the compounds , phosphoramide, glucoside, ether, acetal and other forms.
- compositions and methods of administration are provided.
- the present invention also provides a pharmaceutical composition, comprising:
- the compound of the present invention has excellent antitumor activity, the compound of the present invention and its various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and drugs containing the compound of the present invention as the main active ingredient
- the composition can be used for the treatment, prevention and alleviation of tumor-related diseases.
- the pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier within a safe and effective amount range.
- safe and effective dose refers to: the amount of the compound is sufficient to obviously improve the condition without causing severe side effects.
- the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 10-1000 mg of the compound of the present invention per dose.
- the "one dose” is a capsule or tablet.
- “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and low enough toxicity. "Compatibility” herein means that the components of the composition can be blended with the compound of the present invention and with each other without significantly reducing the efficacy of the compound.
- Examples of pharmaceutically acceptable carrier parts include cellulose and derivatives thereof (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid , magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agent (such as sodium lauryl sulfate), coloring agent, flavoring agent, stabilizer, antioxidant, preservative, pyrogen-free water, etc.
- cellulose and derivatives thereof such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- gelatin such as talc
- solid lubricants such as stearic acid , magnesium stearate
- calcium sulfate such
- the pharmaceutical composition is injection, capsule, tablet, pill, powder or granule.
- the mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration .
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) fillers or extenders, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, For example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow agents, such as paraffin; (f) Absorption accelerators such as quaternary ammonium compounds; (g) wetting agents such as cetyl alcohol and glyceryl monostea, or
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shell materials, such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner.
- coatings and shell materials such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner.
- Examples of usable embedding components are polymeric substances and waxy substances.
- the active compounds can also be in microencapsulated form, if desired, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
- liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.
- inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and
- compositions can also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Suspensions in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
- suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
- compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- Suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
- Dosage forms for topical administration of a compound of this invention include ointments, powders, patches, sprays and inhalants.
- the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required, if necessary.
- the compound of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as antineoplastic drugs).
- other pharmaceutically acceptable compounds such as antineoplastic drugs.
- the treatment method of the present invention can be used alone or in combination with other treatment methods or drugs.
- a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage when administered, for a person with a body weight of 60kg, the daily
- the dosage is usually 1-2000 mg, preferably 50-1000 mg.
- factors such as the route of administration and the health status of the patient should also be considered for the specific dosage, which are within the skill of skilled physicians.
- the present invention has the following main advantages:
- the compound has excellent pharmacokinetic properties
- Step 1 Dissolve compound 1a (1eq) in N,N-dimethylformamide, add potassium hydroxide (2eq) and deuteroiodomethane (2.5eq), and react at room temperature for about 3 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound 1b.
- Step 2 Suspend succinic anhydride (1.5eq) in 1,2-dichloroethane, add aluminum chloride (2eq) at 0°C, and then add compound 1b (1eq) to 1,2-dichloro After adding the ethane solution in about 15 minutes, the temperature of the reaction was raised to 45° C. for about 8 hours. After the reaction is complete, slowly pour the reaction solution into water, then neutralize the reaction solution with 4N hydrochloric acid aqueous solution with 3 times the equivalent of aluminum chloride, and filter after stirring for about 30 minutes. The obtained filter cake is beaten with ethanol, and the filtered cake Compound S1 was obtained by drying.
- Step 1 Suspend compound 2a (1eq) in dichloromethane, slowly add aluminum chloride (5eq), heat up to 45°C and react for about 1.5 hours. After the reaction is complete, slowly pour the reaction solution into water, neutralize the reaction solution with 4N hydrochloric acid aqueous solution of 3 times equivalent to aluminum chloride, fully stir until the solution is clear, extract with dichloromethane, collect the organic phase and pass through column purification to obtain Compounds 2b and 2c.
- aluminum chloride 5eq
- Step 2 Dissolve compound 2b (1eq) in N,N-dimethylformamide, add potassium hydroxide (1.5eq) and deuteroiodomethane (1.5eq), and react at room temperature for about 3 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound 2d.
- Step 3 Suspend compound 2d (1eq) in tetrahydrofuran, add lithium hydroxide monohydrate (3eq) in water, and react at room temperature for about 2 hours. After the reaction is complete, spin off most of the organic solvents, then slowly add 1N aqueous hydrochloric acid solution dropwise to the remaining solution, adjust the pH to 5-6, filter after the solid is fully separated, beat the obtained filter cake with ethanol, filter and dry the filter cake Compound S2 was obtained.
- Step 1 Suspend compound S1 (1eq) in methanol, add thionyl chloride (10eq) dropwise under ice-cooling, and react at room temperature for about 8 hours. After the reaction was complete, the reaction solution was spin-dried, the solid was dissolved in ethyl acetate and the pH was adjusted to alkaline with saturated sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound 4a.
- Step 2 Compound 4a (1eq) was dissolved in dichloromethane, then 1-fluoro-2,6-dichloropyridine tetrafluoroborate (3eq) was added, and the temperature was raised to reflux for about 2 hours. After the reaction was complete, the reaction solution was spin-dried and purified by column to obtain compound 4b.
- Step 3 Suspend compound 4b (1eq) in tetrahydrofuran, add an aqueous solution of lithium hydroxide monohydrate (3eq), and react at room temperature for about 2 hours. After the reaction is complete, spin off most of the organic solvents, then slowly add 1N aqueous hydrochloric acid solution dropwise to the remaining solution, adjust the pH to 5-6, filter after the solid is fully separated, beat the obtained filter cake with ethanol, filter and dry the filter cake Compound S4 was obtained.
- Step 1 Dissolve compound 5a (1eq) in dichloromethane under nitrogen atmosphere, add boron tribromide (1.0M solution in dichloromethane, 6eq) dropwise at -78°C, stir for 1 hour and then rise to The reaction was continued at room temperature for about 3 hours. After the reaction was complete, ice water was slowly added to quench, extracted with dichloromethane, and the organic phase was collected and purified by column to obtain compound 5b.
- boron tribromide 1.0M solution in dichloromethane, 6eq
- Step 2 Dissolve compound 5b (1eq) in N,N-dimethylformamide, add potassium hydroxide (2eq) and deuteroiodomethane (2.5eq), and react at room temperature for about 3 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound 5c.
- Step 3 Compound 5c (1eq) was dissolved in acetonitrile, and 1-chloromethyl-4-fluoro-1,4-diazabicyclo[2.2.2]octane bis(tetrafluoroborate) salt (1.1eq ), heated to 45°C and reacted overnight. After the reaction was complete, saturated sodium bicarbonate solution was added, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound 5d.
- Step 4 Suspend compound 5d (1eq) in tetrahydrofuran, add lithium hydroxide monohydrate (3eq) in water, and react at room temperature for about 3 hours. After the reaction is complete, spin off most of the organic solvents, then slowly add 1N aqueous hydrochloric acid solution dropwise to the remaining solution, adjust the pH to 5-6, filter after the solid is fully separated, beat the obtained filter cake with ethanol, filter and dry the filter cake Compound 5e was obtained.
- Step 5 Dissolve compound 5e (1eq) in N-methylpyrrolidone, add silver carbonate (1.2eq), heat up to 170°C and react for about 1 hour. After the reaction was complete, the reaction solution was cooled and filtered, the filtrate was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound 5f.
- Step 6 Suspend (S)-3-methylsuccinic anhydride (1.5eq) in 1,2-dichloroethane, add aluminum chloride (2eq) at 0°C, and then add compound 5f (1eq ) in 1,2-dichloroethane solution, after about 15 minutes, the reaction temperature was raised to 45°C for about 6 hours. After the reaction is complete, slowly pour the reaction solution into water, then neutralize the reaction solution with 3 times the equivalent of 4N hydrochloric acid aqueous solution in aluminum chloride, fully stir for about 30 minutes, extract with ethyl acetate, collect the organic phase and pass through the column for purification. Compound S5 was obtained.
- step 6 of compound S5 replace compound 5f with compound 1b, and perform the same operations to obtain compound S6.
- Step 1 Dissolve compound S1 (1eq) in N,N-dimethylformamide, add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyl Urea hexafluorophosphate (2eq), N,N-diisopropylethylamine (3eq) and methoxyamine hydrochloride (1.5eq) were reacted at room temperature for about 3 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S7.
- Step 1 Under an inert gas atmosphere, dissolve compound 8a (1eq) in N,N-dimethylformamide, add sodium hydride (60%, 1.5eq) in batches under ice bath, and react at 0°C for about After half an hour, deuterated methyl iodide (1.5 eq) was added dropwise at this temperature, and then the temperature was raised to 70° C. for about 3 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate and washed with saturated sodium bicarbonate solution, and the organic phase was collected and purified by column to obtain compound 8b.
- Step 2 Dissolve compound 8b in glacial acetic acid/concentrated hydrochloric acid (volume ratio: 2:1), and heat up to reflux for about 3 hours. After the reaction was complete, the reaction solution was spin-dried to obtain a crude product of compound 8c, which was directly used in the next step without purification.
- Step 3 Dissolve compound 8d (1eq) in N,N-dimethylformamide, add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyl Urea hexafluorophosphate (2eq), N,N-diisopropylethylamine (3eq) and crude compound 8c (1.5eq) were reacted at room temperature for about 3 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S8.
- step 3 of compound S8 replace compound 8d with compound S1, and perform the same operations to obtain compound S9.
- 1 H NMR 400MHz, CD 3 OD
- 3.39(d, J 6.7Hz, 2H)
- 2.49(t, J 6.7Hz, 2H).
- Step 1 Dissolve compound 4a (1eq) in dichloromethane under an inert gas atmosphere, add 1,3-propanedithiol (2eq) and boron trifluoride diethyl ether (48%, 1eq) under ice bath , after reacting at 0° C. for about 1 hour, the reaction was continued at room temperature for about 4 hours. After the reaction was complete, the reaction solution was poured into saturated sodium bicarbonate solution, extracted with dichloromethane, and the organic phase was collected and purified by column to obtain compound 10a.
- Step 2 Dissolve compound 10a (1eq) in dichloromethane, add diethylaminosulfur trifluoride (20eq) at room temperature, and react for about 1 hour. After the reaction was complete, the reaction solution was slowly poured into saturated ammonium chloride solution, extracted with dichloromethane, and the organic phase was collected and purified by column to obtain compound 10b.
- Step 3 Suspend compound 10b (1eq) in tetrahydrofuran, add an aqueous solution of lithium hydroxide monohydrate (3eq), and react at room temperature for about 3 hours. After the reaction was complete, most of the organic solvent was spun off, and then 1N hydrochloric acid aqueous solution was slowly added dropwise to the remaining solution to adjust the pH to 5-6, extracted with dichloromethane, and the organic phase was collected and purified by column to obtain compound S10.
- 1 H NMR 400MHz, CDCl 3 ) ⁇ 7.35(s,1H),7.25(s,1H),7.20(s,1H),2.71–2.63(m,4H).
- Step 1 Synthetic steps refer to compound S7: O-(tert-butyldiphenylsilyl)-N-methylhydroxylamine was used to replace methoxylamine hydrochloride, and other operations were the same to obtain compound 15a.
- Step 2 Dissolve compound 15a (1eq) in tetrahydrofuran, add pyridine hydrofluoride (3eq) under ice-cooling, and react for about 2 hours. After the reaction was complete, the reaction solution was quenched with saturated sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was collected for column purification to obtain compound S15.
- Step 1 Under an inert gas atmosphere, add hydroxylamine hydrochloride (3eq) to potassium hydroxide (3eq) solution in methanol, react for about 30 minutes, then add compound 4a (1eq), and continue the reaction for about 6 hours. After the reaction was complete, it was directly purified by column to obtain compound S16.
- Step 1 Synthetic steps refer to compound 4a: Compound S1 is replaced by compound S5, and other operations are the same to obtain compound 17a.
- Step 2 Synthetic steps refer to compound S10: replace compound 4a with compound 17a, and perform the same operations to obtain compound S17.
- Step 1 Dissolve compound S1 (1eq) in N,N-dimethylformamide, add 2-(1H-benzotrisazoL-1-yl)-1,1,3,3-tetramethyl Urea tetrafluoroborate (2eq), N,N-diisopropylethylamine (3eq) and N-isopropylhydroxylamine hydrochloride (1.5eq) were reacted at room temperature for about 2 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S18.
- the present invention discloses the pharmacokinetics of compound IA without deuterium atom substitution in patent CN111393404A and deuterium-substituted compounds S7, S8, and S9 described in the present invention in rats academic properties were compared.
- mice 12 male SD rats, body weight 223-254g, were randomly divided into 4 groups, 3 rats in each group, given IA/S7/S8/S9 intravenously, and the dosage was 1mg/kg. Fasted overnight before administration, ate food 4 hours after administration, and drank water freely. At 5 min, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 24 h, 60 ⁇ L blood samples were collected from rats through the jugular vein into micro K 2 EDTA tubes, centrifuged at 8000 rpm for 6 min, separated from plasma, and frozen in a -20°C refrigerator.
- the concentration of IA, S7, S8, and S9 in rat plasma was determined by LC-MS/MS, and the pharmacokinetic parameters after administration were calculated using the non-compartmental model of WinNonlin 8.2.0 software (Pharsight, USA).
- THP-1 cells were seeded in a 12-well plate at a density of 6*10 5 /mL, treated with 10 ⁇ M compound after 12 hours, collected by centrifugation at 500 g for 5 minutes after 8 hours, and lysed by adding 1 mL TRIzol to each cell pellet.
- TRIzol operating instructions mRNA was extracted and its concentration was determined.
- 500ng mRNA was used to reverse transcribe it into cDNA using PrimeScriptTM RT Master Mix Kit (TAKARA).
- qPCR Mix Kit TOYOBO
- 480 480
- mice 16 4-6 week-old Balb/C female mice were injected with CT-26 cells (2.5*10 5 ), and the tumor volume grew to 50-100 mm 3 .
- the mice were randomly divided into 2 groups, 8 mice in each group, and the compound S1 (10 mg/kg) was injected intratumorally on the 1st, 4th, and 7th day, respectively, for a total of 3 times.
- Animals were randomly grouped and body weight was recorded, and each mouse in the group was marked after grouping; the body weight and tumor volume of the mice were measured every two days, and the state of the mice was observed and recorded at any time.
- the compound S1 described in the present invention can effectively inhibit tumor growth in the CT26 mouse colorectal cancer model. After intratumoral injection of 10 mg/kg, after 3 administrations, the tumor growth inhibition rate reached 79.74%. .
- the compounds substituted with deuterium described in the present invention have higher activation ability to STING, and the pharmacokinetic properties in rats are improved, which makes the compounds of the present invention enter the body with pharmacodynamics and safety. Its efficacy can be fully exposed during the sexual evaluation, and it has significant advantages and potential for further research and development compared with the STING agonists reported so far.
Abstract
本发明涉及一类含有氘取代的苯并噻吩类衍生物及其制备与用途。具体地,本发明化合物具有式I所示结构,其中各基团和取代基的定义如说明书中所述。所述化合物具有优异的药代动力学性质和STING激动活性。
Description
本发明涉及生物医药领域,具体地涉及一类含有氘取代的苯并噻吩类衍生物及其制备与用途。
干扰素基因刺激因子(STING,stimulator of interferon genes)是固有免疫cGAS-STING信号通路的重要信号蛋白,当cGAS识别到内源或外源dsDNA催化生成的2’,3’-cGAMP可结合并激活STING,促使STING从内质网向高尔基体转运,从而招募TBK1并使其磷酸化,以激活IRF3或NF-κB,进而诱导I型干扰素及其他炎症因子的分泌,最终产生抑制肿瘤生长的效果。这便意味着,激活STING可作为抗肿瘤免疫疗法的策略之一。
目前,已有多款STING激动剂处于临床试验阶段,但其结构类型多数为内源性配体2’,3’-cGAMP的环二核苷类衍生物,此类化合物存在分子量大、稳定性差、大多只能通多瘤内注射给药等缺点,极大地限制了STING激动剂在临床上的应用与发展。开发具有良好药代动力学性质,并具有良好生物活性的STING激动剂是该领域目前亟需开展的工作之一。
在药物研发过程中,氘原子的引入,通常有助于优化药物分子的药代动力学性质延长药物作用时间,或能起到降低药物分子的毒性、增强药物分子的生物活性、增加分子稳定性等作用。目前多家国内外制药企业(如BMS、Concert、苏州泽璟等)均在开展氘代药物研发,并且已有含氘药物成功上市(如氘代丁苯那嗪、多纳非尼),此外,多款氘代药物处于临床试验阶段(如BMS-986165、VX-984、CTP-656、AVP-786等)。可见,氘代药物具有广泛的研究价值以及广阔的应用前景。
发明内容
本发明的目的在于提供一种式I所示化合物及其制备方法和用途。
本发明的第一方面,提供了一种式I所示化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,
其中,
X选自下组:C(O)、CF
2;
Y选自下组:OR
a、NHR
b、N(R
b)
2;
R
1、R
4分别独立地选自下组:氢、卤素;
R
2、R
3分别独立地为氘取代或未取代的C1-C4烷基;
R
5、R
6分别独立地选自下组:氢、卤素、C1-C4烷基;
R
a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);
R
b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、氘、卤素、C1-C4烷基、C6-C10芳基;
附加条件是R
2、R
3、R
a、R
b中至少一个含有氘。
在另一优选例中,
X为C(O);
Y选自下组:OR
a、NHR
b、N(R
b)
2;
R
1、R
4分别独立地选自下组:氢、卤素;
R
2、R
3分别独立地为氘取代的C1-C4烷基;
R
5、R
6分别独立地选自下组:氢、卤素、C1-C4烷基;
R
a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);
R
b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、氘、卤素、C1-C4烷基、C6-C10芳基。
在另一优选例中,
X为C(O);
Y选自下组:OR
a、NHR
b、N(R
b)
2;
R
1、R
4分别独立地选自下组:氢、卤素;
R
2、R
3分别独立地为氘取代的C1-C4烷基;
R
5、R
6分别独立地选自下组:氢、卤素、C1-C4烷基;
R
a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);
R
b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、卤素、C1-C4烷基、C6-C10芳基。
在另一优选例中,
X为CF
2;
Y选自下组:OR
a、NHR
b、N(R
b)
2;
R
1、R
4分别独立地选自下组:氢、卤素;
R
2、R
3分别独立地为氘取代的C1-C4烷基;
R
5、R
6分别独立地选自下组:氢、卤素、C1-C4烷基;
R
a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);
R
b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、氘、卤素、C1-C4烷基、C6-C10芳基。
在另一优选例中,
X为CF
2;
Y选自下组:OR
a、NHR
b、N(R
b)
2;
R
1、R
4分别独立地选自下组:氢、卤素;
R
2、R
3分别独立地为氘取代的C1-C4烷基;
R
5、R
6分别独立地选自下组:氢、卤素、C1-C4烷基;
R
a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);
R
b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、卤素、C1-C4烷基、C6-C10芳基。
在另一优选例中,R
1、R
4分别独立地选自下组:氢、卤素。
在另一优选例中,R
2、R
3分别独立地为一次或多次氘代或全氘代的C1-C4烷基。
在另一优选例中,R
2、R
3分别独立地为一次或多次氘代或全氘代的选自下组的基团:甲基、乙基、丙基、异丙基、丁基、叔丁基。
在另一优选例中,R
2、R
3分别独立地选自下组:全氘代甲基、全氘代乙基、全氘代丙基、全氘代异丙基、全氘代丁基、全氘代叔丁基。
在另一优选例中,R
2、R
3均为全氘代甲基。
在另一优选例中,R
5、R
6分别独立地选自下组:氢、C1-C4烷基。
在另一优选例中,R
a选自下组:氢、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基。
在另一优选例中,R
b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基。
在另一优选例中,R
a是未氘代的。
在另一优选例中,R
b是未氘代的。
在另一优选例中,所述化合物选自下组:
本发明的第二方面,提供了一种药物组合物,包含:
(i)一种或多种治疗有效量的本发明第一方面所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐;和
(ii)药学上可接受的载体。
本发明的第三方面,提供了一种本发明第一方面所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐或本发明第二方面所述的药物组合物的 用途,用于制备制剂,所述制剂用于预防和/或治疗与I型干扰素相关的疾病。
在另一优选例中,所述与I型干扰素相关的疾病选自下组:感染性疾病、癌症、自身免疫病。
在另一优选例中,所述癌症选自下组:乳腺癌、卵巢癌、肝癌、黑色素瘤、***癌、结肠癌、胃癌。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
图1是实施例3化合物S1对肿瘤的抑制结果。
本发明人经过长期而深入的研究,意外地制备了一种具有优异药代动力学性质的式I所示化合物。在此基础上,发明人完成了本发明。
术语
在本发明中,除非特别指出,所用术语具有本领域技术人员公知的一般含义。
在本发明中,术语“卤素”指F、Cl、Br或I。
在本发明中,“C1-C6烷基”是指包括1-6个碳原子的直链或支链的烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、新戊基、特戊基、或类似基团。术语“C1-C4烷基”具有类似含义。
在本发明中,术语“C2-C6烯基”是指具有2-6个碳原子的含有一个双键的直链或支链烯基,非限制性地包括乙烯基、丙烯基、丁烯基、异丁烯基、戊烯基和己烯基等。
在本发明中,术语“C2-C6炔基”是指具有2-6个碳原子的含有一个三键的直链或支链炔基,非限制性地包括乙炔基、丙炔基、丁炔基、异丁炔基、戊炔基和己炔基等。
在本发明中,术语“C3-C8环烷基”是指在环上具有3-8个碳原子的环状烷基,非限制性地包括环丙基、环丁基、环戊基、环己基、环庚基、环辛基等。
在本发明中,术语“C1-C6烷氧基”是指具有1-6个碳原子的直链或支链烷氧基,非限制性地包括甲氧基、乙氧基、丙氧基、异丙氧基和丁氧基等。优选为C1-C4 烷氧基。
在本发明中,术语“芳环”或“芳基”具有相同的含义,优选为“C6-C10芳基”。术语“C6-C10芳基”是指在环上不含杂原子的具有6-10个碳原子的芳香族环基,如苯基、萘基等。
在本发明中,术语“卤代”是指被卤素取代。
在本发明中,术语“氘代”是指被氘取代。
在本发明中,术语“取代”指特定的基团上的一个或多个氢原子被特定的取代基所取代。特定的取代基为在前文中相应描述的取代基,或各实施例中所出现的取代基。除非特别说明,某个取代的基团可以在该基团的任何可取代的位点上具有一个选自特定组的取代基,所述的取代基在各个位置上可以是相同或不同的。本领域技术人员应理解,本发明所预期的取代基的组合是那些稳定的或化学上可实现的组合。所述取代基例如(但并不限于):卤素、羟基、羧基(-COOH)、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、3-至12元杂环基、芳基、杂芳基、C1-C8醛基、C2-C10酰基、C2-C10酯基、氨基、C1-C6烷氧基、C1-C10磺酰基等。
在本发明中,术语1-6个指1、2、3、4、5或6个。其他类似术语各自独立地具有类似含义。
术语“氨基”为-NH2。
应理解,当某一基团同时存在于化合物的多个不同位置时,其在各位置的定义是相互独立的,可以相同也可以不同。亦即,术语“选自下组:”与术语“各独立地选自下组:”具有相同含义。
化合物
本发明提供了式I所示化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,
其中,各基团如上文所定义。
如本文所用,术语“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合 用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于:盐酸、氢溴酸、氢氟酸、硫酸、硝酸、磷酸等无机酸;甲酸、乙酸、三氟乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、苯甲酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、萘磺酸等有机酸;以及脯氨酸、苯丙氨酸、天冬氨酸、谷氨酸等氨基酸。
另一类优选的盐是本发明化合物与碱形成的盐,例如碱金属盐(例如钠盐或钾盐)、碱土金属盐(例如镁盐或钙盐)、铵盐(如低级的烷醇铵盐以及其它药学上可接受的胺盐),例如甲胺盐、乙胺盐、丙胺盐、二甲基胺盐、三甲基胺盐、二乙基胺盐、三乙基胺盐、叔丁基胺盐、乙二胺盐、羟乙胺盐、二羟乙胺盐、三羟乙胺盐,以及分别由吗啉、哌嗪、赖氨酸形成的胺盐。
术语“溶剂合物”指本发明化合物与溶剂分子配位形成特定比例的配合物。“水合物”是指本发明化合物与水进行配位形成的配合物。
此外,本发明化合物还包括式I所示化合物的前药。术语“前药”包括其本身可以是具有生物学活性的或非活性的,当用适当的方法服用后,其在人体内进行代谢或化学反应而转变成式I的一类化合物,或式I的一个化合物所组成的盐或溶液。所述的前药包括(但不局限于)所述化合物的羧酸酯、碳酸酯、磷酸酯、硝酸酯、硫酸酯、砜酯、亚砜酯、氨基化合物、氨基甲酸盐、偶氮化合物、磷酰胺、葡萄糖苷、醚、乙缩醛等形式。
药物组合物和施用方法
本发明还提供了一种药物组合物,包含:
(i)一种或多种治疗有效量的所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐;和
(ii)药学上可接受的载体。
由于本发明化合物具有优异的抗肿瘤活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物可用于治疗、预防以及缓解与肿瘤相关的疾病。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接 受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明化合物/剂,更佳地,含有10-1000mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
所述的药物组合物为注射剂、囊剂、片剂、丸剂、散剂或颗粒剂。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和***胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药,或者与其他药学上可接受的其他化合物(如抗肿瘤药物)联合给药。
本发明治疗方法可以单独施用,或者与其它治疗手段或者治疗药物联用。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选50~1000mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
与现有技术相比,本发明具有以下主要优点:
(1)所述化合物具有优异的药代动力学性质;
(2)所述化合物具有优异的STING激活能力。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发 明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件如Sambrook等人,分子克隆:实验室手册(New York:Cold Spring Harbor Laboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
制备实施例
1.化合物S1的合成
步骤1:将化合物1a(1eq)溶于N,N-二甲基甲酰胺中,加入氢氧化钾(2eq)和氘代碘甲烷(2.5eq),于室温下反应约3小时。待反应完全后,将反应液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物1b。
步骤2:将丁二酸酐(1.5eq)悬浮于1,2-二氯乙烷中,0℃下加入氯化铝(2eq),而后逐滴加入化合物1b(1eq)的1,2-二氯乙烷溶液,约15分钟加毕后,将反应升温至45℃反应约8小时。待反应完全后,将反应液缓慢倾入水中,而后用3倍当量于氯化铝的4N盐酸水溶液中和反应液,充分搅拌约30分钟后过滤,所得滤饼用乙醇打浆,过滤后滤饼烘干得化合物S1。
1H NMR(400MHz,DMSO)δ12.18(s,1H),8.20(s,1H),7.59(s,1H),7.47(s,1H),3.26(t,J=6.4Hz,2H),2.60(t,J=6.3Hz,2H).
2.化合物S2的合成
步骤1:将化合物2a(1eq)悬浮于二氯甲烷中,缓慢加入氯化铝(5eq),升温至45℃反应约1.5小时。待反应完全后,将反应液缓慢倾入水中,用3倍当量于氯化铝的4N盐酸水溶液中和反应液,充分搅拌至溶液澄清,用二氯甲烷 萃取,收集有机相过柱纯化,得化合物2b和2c。
步骤2:将化合物2b(1eq)溶于N,N-二甲基甲酰胺中,加入氢氧化钾(1.5eq)和氘代碘甲烷(1.5eq),于室温下反应约3小时。待反应完全后,将反应液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物2d。
步骤3:将化合物2d(1eq)悬浮于四氢呋喃中,加入一水合氢氧化锂(3eq)的水溶液,于室温下反应约2小时。待反应完全后,旋去多数有机溶剂,而后向剩余溶液中缓慢滴加1N盐酸水溶液,调节pH至5~6,待固体充分析出后过滤,所得滤饼用乙醇打浆,过滤后滤饼烘干得化合物S2。
1H NMR(400MHz,DMSO)δ12.19(s,1H),8.20(s,1H),7.59(s,1H),7.48(s,1H),3.86(s,3H),3.26(t,J=6.4Hz,2H),2.60(t,J=6.4Hz,2H).
3.化合物S3的合成
合成步骤参考化合物S2:用化合物2c替换化合物2b,其他步骤相同,得化合物S3。
1H NMR(400MHz,DMSO)δ12.19(s,1H),8.20(s,1H),7.59(s,1H),7.48(s,1H),3.83(s,3H),3.26(t,J=6.4Hz,2H),2.60(t,J=6.4Hz,2H).
4.化合物S4的合成
步骤1:将化合物S1(1eq)悬浮于甲醇中,冰浴下逐滴加入二氯亚砜(10eq),室温下反应约8小时。待反应完全后,将反应液旋干,固体用乙酸乙酯溶解并用饱和碳酸氢钠溶液调节pH至碱性,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物4a。
步骤2:将化合物4a(1eq)溶于二氯甲烷中,随后加入1-氟-2,6-二氯吡啶四氟硼酸盐(3eq),升温至回流反应约2小时。待反应完全后,将反应液旋干,过柱纯化得化合物4b。
步骤3:将化合物4b(1eq)悬浮于四氢呋喃中,加入一水合氢氧化锂(3eq)的水溶液,于室温下反应约2小时。待反应完全后,旋去多数有机溶剂,而后向剩余溶液中缓慢滴加1N盐酸水溶液,调节pH至5~6,待固体充分析出后过滤,所得滤饼用乙醇打浆,过滤后滤饼烘干得化合物S4。
1H NMR(400MHz,DMSO)δ12.18(s,1H),8.20(s,1H),7.59(s,1H),7.47(s,1H),3.26(t,J=6.4Hz,2H),2.60(t,J=6.3Hz,2H).
5.化合物S5的合成
步骤1:在氮气氛围下,将化合物5a(1eq)溶于二氯甲烷中,-78℃下逐滴加入三溴化硼(1.0M的二氯甲烷溶液,6eq),搅拌1小时后升至室温继续反应约3小时。待反应完全后,缓慢加入冰水淬灭,用二氯甲烷萃取,收集有机相过柱纯化,得化合物5b。
步骤2:将化合物5b(1eq)溶于N,N-二甲基甲酰胺中,加入氢氧化钾(2eq)和氘代碘甲烷(2.5eq),于室温下反应约3小时。待反应完全后,将反应液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物5c。
步骤3:将化合物5c(1eq)溶于乙腈中,加入1-氯甲基-4-氟-1,4-二氮杂双环[2.2.2]辛烷二(四氟硼酸)盐(1.1eq),升温至45℃反应过夜。待反应完全后,加入饱和碳酸氢钠溶液,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物5d。
步骤4:将化合物5d(1eq)悬浮于四氢呋喃中,加入一水合氢氧化锂(3eq)的水溶液,于室温下反应约3小时。待反应完全后,旋去多数有机溶剂,而后向 剩余溶液中缓慢滴加1N盐酸水溶液,调节pH至5~6,待固体充分析出后过滤,所得滤饼用乙醇打浆,过滤后滤饼烘干得化合物5e。
步骤5:将化合物5e(1eq)溶于N-甲基吡咯烷酮中,加入碳酸银(1.2eq),升温至170℃反应约1小时。待反应完全后,冷却反应液并过滤,将滤液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物5f。
步骤6:将(S)-3-甲基丁二酸酐(1.5eq)悬浮于1,2-二氯乙烷中,0℃下加入氯化铝(2eq),而后逐滴加入化合物5f(1eq)的1,2-二氯乙烷溶液,约15分钟加毕后,将反应升温至45℃反应约6小时。待反应完全后,将反应液缓慢倾入水中,而后用3倍当量于氯化铝的4N盐酸水溶液中和反应液,充分搅拌约30分钟后用乙酸乙酯萃取,收集有机相过柱纯化,得化合物S5。
1H NMR(400MHz,CDCl
3)δ7.96(s,1H),7.07(s,1H),3.48(dd,J=17.2,7.7Hz,1H),3.23–3.12(m,1H),3.07(dd,J=17.2,5.7Hz,1H),1.34(d,J=7.2Hz,3H).
6.化合物S6的合成
合成步骤参考化合物S5的步骤6:用化合物1b替换化合物5f,其他操作相同,得化合物S6。
1H NMR(400MHz,CDCl
3)δ7.82(s,1H),7.25(s,1H),7.24(s,1H),3.96(d,J=10.7Hz,6H),2.62(s,3H).
7.化合物S7的合成
步骤1:将化合物S1(1eq)溶于N,N-二甲基甲酰胺中,加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(2eq),N,N-二异丙基乙胺(3eq)和甲氧基胺盐酸盐(1.5eq),于室温下反应约3小时。待反应完全后,将反应 液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物S7。
1H NMR(400MHz,DMSO)δ11.07(s,1H),8.20(s,1H),7.59(s,1H),7.47(s,1H),3.57(s,3H),3.27(t,J=6.7Hz,2H),2.35(t,J=6.6Hz,2H).
8.化合物S8的合成
步骤1:在惰性气体氛围下,将化合物8a(1eq)溶于N,N-二甲基甲酰胺中,在冰浴下分批加入氢化钠(60%,1.5eq),于0℃反应约半小时后,在该温度下逐滴加入氘代碘甲烷(1.5eq),随后升温至70℃反应约3小时。待反应完全后,将反应液倾入水中,用乙酸乙酯萃取并用饱和碳酸氢钠溶液洗涤,收集有机相过柱纯化,得化合物8b。
步骤2:将化合物8b溶于冰醋酸/浓盐酸(体积比为2:1)中,升温至回流反应约3小时。待反应完全后,将反应液旋干,得化合物8c的粗品,不作纯化直接用于下一步。
步骤3:将化合物8d(1eq)溶于N,N-二甲基甲酰胺中,加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(2eq),N,N-二异丙基乙胺(3eq)和化合物8c的粗品(1.5eq),于室温下反应约3小时。待反应完全后,将反应液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物S8。
1H NMR(400MHz,CD
3OD)δ8.09(s,1H),7.44(s,2H),3.93(s,3H),3.91(s,3H),3.38(t,J=6.7Hz,2H),2.49(t,J=6.7Hz,2H).
9.化合物S9的合成
合成步骤参考化合物S8的步骤3:用化合物S1替换化合物8d,其他操作相同,得化合物S9。
1H NMR(400MHz,CD
3OD)δ8.09(s,1H),7.44(s,2H),3.39(d, J=6.7Hz,2H),2.49(t,J=6.7Hz,2H).
10.化合物S10的合成
步骤1:在惰性气体氛围下,将化合物4a(1eq)溶于二氯甲烷中,在冰浴下加入1,3-丙二硫醇(2eq)和三氟化硼***(48%,1eq),于0℃反应约1小时后,升至室温继续反应约4小时。待反应完全后,将反应液倾入饱和碳酸氢钠溶液中,用二氯甲烷萃取,收集有机相过柱纯化,得化合物10a。
步骤2:将化合物10a(1eq)溶于二氯甲烷中,室温下加入二乙胺基三氟化硫(20eq),反应约1小时。待反应完全后,将反应液缓慢倾入饱和氯化铵溶液中,用二氯甲烷萃取,收集有机相过柱纯化,得化合物10b。
步骤3:将化合物10b(1eq)悬浮于四氢呋喃中,加入一水合氢氧化锂(3eq)的水溶液,于室温下反应约3小时。待反应完全后,旋去多数有机溶剂,而后向剩余溶液中缓慢滴加1N盐酸水溶液,调节pH至5~6,用二氯甲烷萃取,收集有机相过柱纯化,得化合物S10。
1H NMR(400MHz,CDCl
3)δ7.35(s,1H),7.25(s,1H),7.20(s,1H),2.71–2.63(m,4H).
11.化合物S11的合成
合成步骤参考化合物S7:用化合物S2替换化合物S1,其他操作相同,得化合物S11。
1H NMR(400MHz,DMSO)δ11.07(s,1H),8.20(s,1H),7.59(s,1H),7.48(s,1H),3.86(s,3H),3.57(s,3H),3.27(t,J=6.7Hz,2H),2.35(t,J=6.5Hz,2H).
12.化合物S12的合成
合成步骤参考化合物S7:用化合物S3替换化合物S1,其他操作相同,得化合物S12。
1H NMR(400MHz,DMSO)δ11.07(s,1H),8.20(s,1H),7.59(s,1H),7.48(s,1H),3.83(s,3H),3.57(s,3H),3.27(t,J=6.7Hz,2H),2.35(t,J=6.5Hz,2H).
13.化合物S13的合成
合成步骤参考化合物S7:用O-苯甲基羟胺替换甲氧基胺盐酸盐,其他操作相同,得化合物S13。
1H NMR(400MHz,CDCl
3)δ8.39(s,1H),7.89(s,1H),7.41–7.36(m,5H),7.25(d,J=1.6Hz,2H),4.91(s,2H),3.37(t,J=6.0Hz,2H),2.50(br,2H).
14.化合物S14的合成
合成步骤参考化合物S7:用甲氧基甲基胺替换甲氧基胺盐酸盐,其他操作相同,得化合物S14。
1H NMR(400MHz,DMSO)δ8.20(s,1H),7.59(s,1H),7.47(s,1H),3.68(s,3H),3.26(t,J=6.4Hz,2H),2.65(s,3H),2.60(t,J=6.3Hz,2H).
15.化合物S15的合成
步骤1:合成步骤参考化合物S7:用O-(叔丁基二苯基甲硅烷基)-N-甲基羟胺 替换甲氧基胺盐酸盐,其他操作相同,得化合物15a。
步骤2:将化合物15a(1eq)溶于四氢呋喃中,冰浴下加入吡啶氢氟酸盐(3eq),反应约2小时。待反应完全后,用饱和碳酸氢钠溶液淬灭反应液,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物S15。
1H NMR(400MHz,DMSO)δ9.89(s,1H),8.19(s,1H),7.59(s,1H),7.48(s,1H),3.22(t,J=6.4Hz,2H),3.08(s,3H),2.77(t,J=6.2Hz,2H).
16.化合物S16的合成
步骤1:在惰性气体氛围下,将氢氧化钾(3eq)溶液甲醇中,加入盐酸羟胺(3eq),反应约30分钟后加入化合物4a(1eq),继续反应约6小时。待反应完全后,直接过柱纯化,得化合物S16。
1H NMR(400MHz,DMSO)δ10.45(s,1H),8.69(s,1H),8.21(s,1H),7.59(s,1H),7.47(s,1H),3.26(t,J=6.6Hz,2H),2.33(t,J=6.4Hz,2H).
17.化合物S17的合成
步骤1:合成步骤参考化合物4a:用化合物S5替换化合物S1,其他操作相同,得化合物17a。
步骤2:合成步骤参考化合物S10:用化合物17a替换化合物4a,其他操作相同,得化合物S17。
1H NMR(400MHz,CDCl
3)δ7.47(s,1H),7.08(s,1H),2.98–2.83(m,2H),2.39–2.26(m,1H),1.34(d,J=6.6Hz,3H).
18.化合物S18的合成
步骤1:将化合物S1(1eq)溶于N,N-二甲基甲酰胺中,加入2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯(2eq),N,N-二异丙基乙胺(3eq)和N-异丙基羟胺盐酸盐(1.5eq),于室温下反应约2小时。待反应完全后,将反应液倾入水中,用乙酸乙酯萃取,收集有机相过柱纯化,得化合物S18。
1H NMR(400MHz,CDCl
3)δ7.89(s,1H),7.35(br,1H),7.25(s,1H),7.25(s,1H),3.37(t,J=6.8Hz,2H),3.29–3.23(m,2H),2.83(t,J=6.8Hz,2H),1.12(d,J=6.3Hz,6H).
测试实施例
实施例1 化合物S7的药代动力学(PK)性质研究
为了显示氘原子取代后的原子效应,本发明将公开专利CN111393404A中不含氘原子取代的化合物ⅠA与本发明中所描述的含氘取代的化合物S7、S8、S9在大鼠体内的药代动力学性质进行了比较。
实验方法:雄性SD大鼠12只,体重223-254g,随机分成4组,每组3只,静脉给予ⅠA/S7/S8/S9,给药剂量为1mg/kg。给药前禁食过夜,给药后4h统一进食,自由饮水。在5min,0.25,0.5,1.0,2.0,4.0,8.0和24h通过颈静 脉从大鼠身上采集60μL血液样本到微型K
2EDTA管中,8000rpm离心6min,分离血浆,于-20℃冰箱中冷冻。
采用LC-MS/MS法测定大鼠血浆中ⅠA、S7、S8、S9的浓度,采用WinNonlin 8.2.0软件(美国Pharsight公司)的非房室模型计算给药后的药代动力学参数。
实验结果:如表1所示。
表1.化合物IA、S7、S8、S9在大鼠中药代动力学性质对比
以上数据显示,相比于专利CN111393404A中的化合物ⅠA,苯环上的两个甲氧基氘代化合物S7静脉给药暴露量(AUC
last)及最大血药浓度(C
max)显著提高,是化合物ⅠA的8倍以上,并且具有显著降低的清除率;末端氮甲氧基氘代物S8及同时对两部分进行氘代的S9药代性质提升不明显。由此可见,化合物氘代的位置对化合物代谢性质改善的程度密切相关,本发明中所描述的苯环上的两个甲氧基氘代能够显著改善药代动力学性质。
此外,按照本实施例相同的方法得到化合物ⅡA和化合物S1的药代性质如表2所示。
表2
以上数据显示,相比于专利WO2018067423中的化合物ⅡA,本发明中所描述的含氘取代的化合物S1的半衰期(t
1/2)、稳态分布体积(Vss)、口服生物利用度(F)均得到了明显提升。
实施例2 部分化合物对THP-1细胞中IFNb、CXCL10 mRNA表达量的影响
实验方法:THP-1细胞以6*10
5/mL密度接种于12孔板,12h后加入10μM化合物处理,8h后500g离心5min收集细胞,每份细胞沉淀中加入1mL TRIzol裂解细胞。按照TRIzol操作说明提取mRNA并测定其浓度,根据测定结果取500ng mRNA使用PrimeScriptTM RT Master Mix试剂盒(TAKARA)将其反转录为cDNA,使用
qPCR Mix试剂盒(TOYOBO)与
480(Roche)对样品中靶基因含量进行测定,采用2^(-ΔΔCt)相对定量法计算目的基因含量。
实验结果:如表3所示。
表3.化合物对THP-1细胞中IFNb、CXCL10 mRNA表达量的影响
以上活性数据说明,本发明中的化合物对STING具有显著的激活活性。
为了验证不同位置氘取代对化合物的活性的影响,我们对比化合物IA、S7、S8和S9对STING的激动活性(表4)。苯环上的两个甲氧基氘代化合物S7活性显著提升,末端氮甲氧基氘代物S8的活性较IA下降近9倍,同时对两部分进行氘代的S9活性较IA仍然显著下降。由此可见,本发明中所描述的苯环上两个甲氧基氘代的化合物不仅能够显著改善化合物的代谢性质,而且能够提升对STING的激动活性。
表4.化合物IA不同位点氘代物对THP-1细胞中IFNb、CXCL10 mRNA表达量的影响
实施例3 化合物S1在CT26小鼠结直肠癌模型中的体内药效
实验方法:4-6周龄Balb/C雌性小鼠16只,每只小鼠各注射CT-26细胞(2.5*10
5),待肿瘤体积长到50-100mm
3。将小鼠随机分为2组,每组8只,分 别在第1、4、7天经瘤内注射给化合物S1(10mg/kg),共3次。动物随机分组并记录体重,分组后对组内每只小鼠进行标记;每两天测量一次老鼠体重以及肿瘤体积,随时观察老鼠状态并进行记录。
实验结果:如图1所示。
从图1可知,本发明中所描述的化合物S1在CT26小鼠结直肠癌模型中能够有效抑制肿瘤生长,瘤内注射给药10mg/kg,给药3次后,肿瘤生长抑制率达79.74%。
由此可见,本发明所描述的含氘取代后的化合物对STING具有较高的激活能力,在大鼠体内的药代动力学性质得到改善,这使得本发明的化合物进入体内药效学和安全性评价时其药效得以充分暴露,与迄今报道的STING激动剂相比具有显著的优势和进一步研发的潜力。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (10)
- 一种式I所示化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,其中,X选自下组:C(O)、CF 2;Y选自下组:OR a、NHR b、N(R b) 2;R 1、R 4分别独立地选自下组:氢、卤素;R 2、R 3分别独立地为氘取代或未取代的C1-C4烷基;R 5、R 6分别独立地选自下组:氢、卤素、C1-C4烷基;R a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);R b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、氘、卤素、C1-C4烷基、C6-C10芳基;附加条件是R 2、R 3、R a、R b中至少一个含有氘。
- 如权利要求1所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,其特征在于,X为C(O);Y选自下组:OR a、NHR b、N(R b) 2;R 1、R 4分别独立地选自下组:氢、卤素;R 2、R 3分别独立地为氘取代的C1-C4烷基;R 5、R 6分别独立地选自下组:氢、卤素、C1-C4烷基;R a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4 亚烷基);R b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、氘、卤素、C1-C4烷基、C6-C10芳基。
- 如权利要求1所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,其特征在于,X为C(O);Y选自下组:OR a、NHR b、N(R b) 2;R 1、R 4分别独立地选自下组:氢、卤素;R 2、R 3分别独立地为氘取代的C1-C4烷基;R 5、R 6分别独立地选自下组:氢、卤素、C1-C4烷基;R a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);R b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、卤素、C1-C4烷基、C6-C10芳基。
- 如权利要求1所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,其特征在于,X为CF 2;Y选自下组:OR a、NHR b、N(R b) 2;R 1、R 4分别独立地选自下组:氢、卤素;R 2、R 3分别独立地为氘取代的C1-C4烷基;R 5、R 6分别独立地选自下组:氢、卤素、C1-C4烷基;R a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:氘、C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);R b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、氘、卤 素、C1-C4烷基、C6-C10芳基。
- 如权利要求1所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐,其特征在于,X为CF 2;Y选自下组:OR a、NHR b、N(R b) 2;R 1、R 4分别独立地选自下组:氢、卤素;R 2、R 3分别独立地为氘取代的C1-C4烷基;R 5、R 6分别独立地选自下组:氢、卤素、C1-C4烷基;R a选自下组:氢、取代或未取代的C1-C4烷基、取代或未取代的氨基,所述取代指被选自下组的1-4个取代基取代:C1-C4烷基、C6-C10芳基、C6-C10芳基-(C1-C4亚烷基);R b每次出现时均独立地选自下组:氢、取代或未取代的C1-C4烷基、羟基、取代或未取代的C1-C4烷氧基,所述取代指被选自下组的1-4个取代基取代:氢、卤素、C1-C4烷基、C6-C10芳基。
- 一种药物组合物,其特征在于,包含:(i)一种或多种治疗有效量的权利要求1或6所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐;和(ii)药学上可接受的载体。
- 一种权利要求1或6所述的化合物、或其异构体、前药、溶剂合物、水合物或其药学上可接受的盐或权利要求7所述的药物组合物的用途,其特征在于,用于制备制剂,所述制剂用于预防和/或治疗与I型干扰素相关的疾病。
- 如权利要求8所述的用途,其特征在于,所述与I型干扰素相关的疾病选自下组:感染性疾病、癌症、自身免疫病。
- 如权利要求9所述的用途,其特征在于,所述癌症选自下组:乳腺癌、卵巢癌、肝癌、黑色素瘤、***癌、结肠癌、胃癌、胰腺癌、胆管癌、头颈癌、脑胶质瘤、子宫内膜瘤、肺癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111050769.0A CN115772154B (zh) | 2021-09-08 | 2021-09-08 | 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 |
CN202111050769.0 | 2021-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023036195A1 true WO2023036195A1 (zh) | 2023-03-16 |
Family
ID=85388135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/117613 WO2023036195A1 (zh) | 2021-09-08 | 2022-09-07 | 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115772154B (zh) |
WO (1) | WO2023036195A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019027857A1 (en) * | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER |
CN110036001A (zh) * | 2016-10-04 | 2019-07-19 | 默沙东公司 | 作为STING激动剂的苯并[b]噻吩化合物 |
CN111393404A (zh) * | 2019-01-02 | 2020-07-10 | 中国科学院上海药物研究所 | 一类苯并噻吩类化合物及其药物组合物及应用 |
CN111971277A (zh) * | 2018-04-03 | 2020-11-20 | 默沙东公司 | 作为sting激动剂的苯并噻吩及相关化合物 |
WO2021113679A1 (en) * | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
CN113518776A (zh) * | 2019-04-30 | 2021-10-19 | 四川科伦博泰生物医药股份有限公司 | 苯并噻吩类化合物及其制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111393405B (zh) * | 2019-01-02 | 2022-11-25 | 中国科学院上海药物研究所 | 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用 |
-
2021
- 2021-09-08 CN CN202111050769.0A patent/CN115772154B/zh active Active
-
2022
- 2022-09-07 WO PCT/CN2022/117613 patent/WO2023036195A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110036001A (zh) * | 2016-10-04 | 2019-07-19 | 默沙东公司 | 作为STING激动剂的苯并[b]噻吩化合物 |
WO2019027857A1 (en) * | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER |
CN111971277A (zh) * | 2018-04-03 | 2020-11-20 | 默沙东公司 | 作为sting激动剂的苯并噻吩及相关化合物 |
CN111393404A (zh) * | 2019-01-02 | 2020-07-10 | 中国科学院上海药物研究所 | 一类苯并噻吩类化合物及其药物组合物及应用 |
CN113518776A (zh) * | 2019-04-30 | 2021-10-19 | 四川科伦博泰生物医药股份有限公司 | 苯并噻吩类化合物及其制备方法和用途 |
WO2021113679A1 (en) * | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
Also Published As
Publication number | Publication date |
---|---|
CN115772154B (zh) | 2024-04-30 |
CN115772154A (zh) | 2023-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115335379B (zh) | 含螺环的喹唑啉化合物 | |
KR102622161B1 (ko) | 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법 | |
CA3088927A1 (en) | Biaryl derivative, preparation method therefor and pharmaceutical use thereof | |
WO2018157842A1 (zh) | 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途 | |
EP3904351A1 (en) | Fak inhibitor and drug combination thereof | |
KR20210024574A (ko) | 세포 괴사 억제제 및 이의 제조 방법과 용도 | |
EP2964225B1 (en) | CaMKII INHIBITORS AND USES THEREOF | |
EP3189052B1 (en) | Camkii inhibitors and uses thereof | |
CN112174950A (zh) | 杂环衍生物、包含其的药物组合物及其用途 | |
WO2023036195A1 (zh) | 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 | |
WO2015113521A1 (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
CA3125505C (en) | Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof | |
JP7266676B2 (ja) | チエノピリドン誘導体のカリウム塩一水和物及びその調製方法 | |
CN109748914B (zh) | 吡啶并嘧啶类化合物及其应用 | |
CN109384727B (zh) | 酞嗪酮类化合物、其制备方法、药物组合物及用途 | |
CN115340526B (zh) | 邻二甲酰亚胺类化合物及其药物组合物、制备方法和用途 | |
CN111057069B (zh) | 一种环状化合物、其应用及组合物 | |
WO2021092892A1 (zh) | 喹啉或喹唑啉类化合物在制备抗肿瘤药物中的应用 | |
CN117430522A (zh) | 一种gpr139受体激动剂及其制备方法 | |
EP3677581A1 (en) | Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof | |
WO2024051816A1 (zh) | 双环类prmt5抑制剂 | |
WO2024022520A1 (zh) | 适用于抗体-药物偶联物的毒素分子 | |
TW202306955A (zh) | 作為atr抑制劑的萘啶衍生物及其製備方法 | |
WO2021129602A1 (zh) | 取代的多环化合物及其药物组合物和用途 | |
CN116969938A (zh) | 具有抗肿瘤活性的Eudistomin Y类共价衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22866658 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |